Identification of in vitro immunogenic T-cell epitopes is important for the design of immunotherapeutics targeted to specific antigenic sites. To identify candidate cytotoxic T-lymphocyte (CTL) epitopes in the protease of human immunodeficiency virus type 1 (HIV-1) strain MN, we synthesized 9-mer and 10mer peptides containing the HLA-A*0201 binding motif. Binding affinity of the peptides was measured by HLA-A*0201 up-regulation on T2 cells. Peptides with high binding-affinity were tested for their ability to stimulate primary CTLs from healthy HIVnegative blood donors. Peptide-specific CTLs were 0001-4634 # 1997 SGM CCBH Downloaded from www.microbiologyresearch.org by
Introduction
In human immunodeficiency virus (HIV) infections, high numbers of virus-specific cytotoxic T-lymphocytes (CTLs) have been demonstrated in peripheral blood (Moss et al., 1995) . As in many other viral infections, CTLs may be involved in the reduction of acute phase viraemia (Koup et al., 1994) and cell-mediated, antiviral immunity seems to suppress HIV replication during the latent, asymptomatic phase (Walker et al., 1987 ; Tsubota et al., 1989 ; Levy, 1996) . Further evidence supporting the protective role of CTLs was shown in apparently virus-exposed prostitutes and sexual partners (Langlade et al., 1994) , in uninfected infants born to HIV-positive mothers (Demaria et al., 1994) and in seronegative health-care workers occupationally exposed to HIV-contaminated body fluids (Pinto et al., 1995) , who remained permanently seronegative but mounted strong virusspecific CTL responses, which probably eliminated the infection . obtained from five out of six donors by stimulation with a 9-mer (LVGPTPVNI) or a 10-mer (VLVGPTPVNI) peptide derived from a highly conserved amino acid stretch in the C-terminal region of the protease. Addition of peptide-specific CTLs to acutely HIV-infected lymphocytes resulted in inhibition of p24 gag production. In conclusion, a highly conserved HIV protease peptide regularly elicits peptide-specific CTLs. Targeting immune responses against defined epitopes in non-variable regions may be a feasible way to minimize the risk of virus escape from immune surveillance.
However, even vigorous T-cell responses are not sufficient to prevent progression to symptomatic disease in most HIVinfected persons. This failure is plausibly explained by the variability of the virus ; emerging escape variants with critical changes in the dominant epitopes may overgrow and shift the T-cell responses to other epitopes. The escape from the immune response and the undulating T-cell activity are associated with higher overall virus load and rapid decrease in CD4 + cell number (Phillips et al., 1991) . Naturally occurring mutations that allow escape from T-cell recognition have also been demonstrated for CTL epitopes in the more conserved viral proteins, for instance, in the Gag and Nef proteins (Couillin et al., 1995) and one mutant epitope can even antagonize CTLs specific for the other (Klenerman et al., 1994) . On the other hand, long-term non-progressors, who reveal a long-lasting balance between the host and virus replication, possessed stable CTL responses against those epitopes that were antigenically identical in the co-existing virus variants (Nowak et al., 1995 ; .
These findings imply that stimulation of the T-cells of infected individuals by invariant epitopes would stabilize the cellular immunity controlling virus replication and would slow down or even prevent disease progression (Nowak et al., 1995) . The invariant epitopes, one of which has already been identified in the reverse transcriptase (RT) (Vanderburg et al., 1995) , are apparently subdominant (cryptic) in most, if not all, virus-infected persons. This means that a potential recombinant vaccine expressing whole virus proteins would also fail to evoke immune responses to these epitopes. Stimulation with synthetic peptide epitopes is a feasible method to resolve this problem and allows CTL responses to be directed against welldefined antigenic sites (Vanderburg et al., 1995 ; Vitiello et al., 1995) . CD8 + CTLs recognize 8-11 residue peptide fragments that bind with high affinity to MHC class I molecules (Gotch et al., 1987) . Such peptides can be added exogenously and bind to high numbers of surface-exposed MHC molecules (Kageyama et al., 1995) , which is sufficient to stimulate T-cells.
In the present study, we searched for candidate CTL epitopes in the viral protease of strain MN, the prototype strain for HIV-1 infections in Sweden. The protease is wellconserved among HIV strains and can also be recognized by CTLs in vivo (Lamhamedicherradi et al., 1995) . Based on the presence of the refined HLA-A*0201 binding motif (Kast et al., 1994) , nine and ten amino-acid-long peptides were tested for their ability to bind to HLA-A*0201 molecules on the surface of live T2 cells (Salter & Cresswell, 1986 ; Stuber et al., 1995) . The peptides with high binding-affinity were used in vitro to stimulate cytotoxic lymphocytes.
Methods
Peptide binding assay. Peptides with free carboxyl ends were synthesized by F-moc chemistry. Homogeneity of peptides was 90 % as determined by HPLC. HLA-A*0201 binding was measured as previously described (Stuber et al., 1995) . Briefly, the peptide-processingdefective T2 cell line (Salter & Cresswell, 1986 ) was seeded into 96-well plates (10& cells per well) and incubated with the peptides overnight at 37 mC in RPMI 1640 medium buffered with 10 mM HEPES. The next day, the plate was put on ice and stained with the HLA-A2-specific monoclonal antibody BB7.2 (diluted in PBS, 1 : 1000) followed by a rabbit anti-mouse immunoglobulin-FITC conjugate (DAKO, 1 : 40 in PBS). After each step, the cells were washed three times in ice-cold PBS. Fluorescence intensity (FI) was measured in a flow cytometer (FACSort, Becton Dickinson). Samples with mean FI above the mean FI of cells incubated without peptide plus 2iSD were regarded as positive.
In vitro CTL stimulation. For stimulation, we used peripheral blood mononuclear cells (PBMCs) or CD8-selected (Dynabeads, Dynal) lymphocytes from healthy, HLA-A2-positive blood donors. Presence of the HLA-A2 allele was determined by fluorescent staining with BB7.2. Autologous PBMCs or enriched dendritic cells (DCs) were used as antigen-presenting cells (APC). For DC separation, whole PBMCs were incubated overnight on plastic in complete medium ; thereafter DCs were enriched by centrifugation of the non-adherent cells on a metrizamide gradient (14n5 g to 100 ml RPMI 1640 medium, 10 % FCS ; Macatonia et al., 1991) . The APCs were pulsed with peptide (10 µM) for 2 h at 26 mC, and then the unbound peptide was washed off. Freshly isolated lymphocytes were co-cultivated with peptide-loaded APCs at a 20 : 1 ratio in complete medium (RPMI 1640, 12n5 mM HEPES, 8 % pooled human serum from five healthy donors, 2 mM glutamine, 100 U\ml penicillin G and 100 µg\ml streptomycin). For weekly restimulation of the cultures, frozen aliquots of autologous PBMCs were thawed, regenerated overnight in complete medium, thereafter irradiated (35 Gy), pulsed with peptides and added to the lymphocyte cultures. At each restimulation, the medium was replaced with fresh complete medium with 5 U\ml recombinant IL-2 (rIL-2 ; Amersham). After 4 weeks, further weekly restimulations were done with a mixture of irradiated (35 Gy) peptide-loaded PBMCs from two or three donors. Between the restimulations, half of the medium was replaced by fresh rIL-2-containing (5 U\ml) medium from one to three times weekly depending on the growth of the individual cultures.
Cytotoxicity assay. The peptide-stimulated cultures were tested in a standard &"Cr-release assay. Effector cells were used 5-7 days after the last stimulation and were suspended in fresh complete medium. HLA-A2matched, Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (established in our department) and an HLA-A2-transfected Jurkat cell line [Jurkat-HLA-A2, kindly provided by Linda Sherman (Irwin et al., 1989) ] were used as targets. The target cells were labelled with 100 µCi &"Cr (1 h, 37 mC) and washed twice. Aliquots were pulsed with 50 µM peptide for 30 min at 26 mC, then appropriately diluted and distributed into 96-well plates (5i10$ target cells into each well). The cells were incubated together for 5 h at 37 mC in a CO # atmosphere. Specific lysis (%) was calculated as follows : 100i(&"Cr release into supernatantspontaneous release)\(total release in detergent-spontaneous release). Peptide-specific CTL activity was evaluated by comparing the specific lysis of the target cells incubated with and without peptide. In peptidetitration experiments, target cells were incubated with different concentrations of peptides for 30 min at 26 mC in a 96 well plate (5i10$ cells in 20 µl complete medium into each well) ; thereafter, effectors were added in 100 µl complete medium. The final peptide concentrations were 1000 nM, 300 nM, 100 nM, 30 nM, 10 nM, 3 nM, 1 nM and 300 pM.
In vitro HIV inhibition assay. PBMCs stimulated with 2 µg\ml PHA for 3 days were infected with HIV-1 strain MN for 4 h. Viruscontaining supernatant with 20 000 c.p.m. of RT activity was added to 10' cells. After centrifugation, the cells were distributed into 48-well plates (3i10& cells per well), and then peptide-stimulated CTL cultures were added at various effector : target ratios. The assay was set up 1 week after the last peptide stimulation of the CTL cultures. After 10 days of incubation, supernatants were collected and the p24 gag content was measured by ELISA (Sundqvist et al., 1989) . Briefly, supernatants were added to wells coated with polyclonal rabbit anti-Gag. Bound antigen was detected with a mixture of three different, horseradish peroxidaseconjugated, monoclonal antibodies to p24 gag . In each test, standard dilution of recombinant p24 gag was run simultaneously.
Results
The peptides from the HIV-1 strain MN protease were selected according to the refined HLA-A*0201 binding motif (Kast et al., 1994) . This motif prefers L or M at the second and L, V or I at the C-terminal anchor positions. A few conservative changes are also tolerated, namely I, V, A or T as second and A, M or T as C-terminal residues. In the protease, we found 26 9-mer or 10-mer peptides that contained either two preferred amino acids or one preferred and one tolerated amino acid in the anchor positions.
A standard HLA-A2 up-regulation assay on the antigenprocessing-deficient T2 cell line was used to measure HLA-A*0201 binding affinities of the synthesized peptides (Stuber et al., 1995) HIV-1 protease-peptide-specific CTLs HIV-1 protease-peptide-specific CTLs concentration, and then the binding peptides were further titrated in serial twofold dilution steps. The relative bindingaffinity of the peptides was expressed as the peptide concentration that induced half-maximal HLA-A*0201 up-regulation (C "/#max ). As positive controls, we included the HLA-A*0201-restricted CTL epitopes of HIV RT (Pol 476-484) (Walker et al., 1988) , human papillomavirus (HPV) type 16 E7 (12-20) (Ressing et al., 1995) and the influenza virus matrix (58-66, F62K) (Gotch et al., 1987) . All six peptides that bound to HLA-A*0201 with high affinity (Table 1 ) originated from well-conserved parts of the HIV protease. Two of them revealed alterations only in the HIV-CPZ group (Myers et al., 1996) , while the other four peptides show only single, conservative amino acid variations in the strains derived from human infections (Table 1) .
For CTL stimulation, PBMC samples were obtained from uninfected, healthy, HLA-A2-positive blood donors. In contrast to studies on CTLs from HIV-infected persons, our purpose was to find peptide epitopes capable of stimulating naive CTL precursors not primed by the infection. The presentation of peptide epitopes was mimicked by loading the synthetic peptides onto APCs, of which the DCs are the most potent, especially in activation of the naive, unprimed T-cell precursors (Croft, 1994) . Thus, in the initial phase of the study, we used enriched DCs as APCs in the start culture. For instance, the peptide-specific CTL culture from donor 2 was obtained in this way from the purified CD8 + population. Later, unselected PBMCs containing several possible APC types were found to work equally as well as purified DCs, which facilitated the in vitro CTL stimulation from donors 3-6 ( Table  2 ). The two protease peptides that elicited peptide-specific CTLs in our system corresponded to a 9-mer (pr76-84) and a 10-mer (pr75-84) overlapping amino acid stretch. pr75-84 seemed more immunogenic than pr76-84 (peptide-specific CTLs were obtained from four out of four donors versus only one out of four donors), although both peptides bound with high affinity to HLA-A*0201 (Table 1) . As expected, pr76-84 and pr75-84 contained the same epitope, since both peptides were able to sensitize HLA-A2-matched target cells to lysis by the CTL cultures stimulated by either the 9-mer or the 10-mer peptide. The HLA-A2 specificity of a pr75-84-stimulated culture was investigated by cold target inhibition. The high rate of specific lysis of &"Cr-labelled peptide-pulsed Jurkat-CCBJ J. Ko! nya and others J. Ko! nya and others Fig. 1 . Peptide-specific lysis of the HLA-A2-positive, lymphoblastoid cell line GK without peptide pre-treatment ( ), pulsed with pr76-84 peptide () or with pr75-84 (>). The peptide-specific CTL lines CTL6/pr76-84 (A) and CTL6/pr75-84 (B) were generated from donor 6 in the presence of pr76-84 and pr75-84 peptides, respectively, and tested at different effector : target ratios (E : T). (C) HLA-A2-specific killing activity by CTL6/pr75-84 of Jurkat-HLA-A2 cells pulsed with pr75-84 (=), of Jurkat-HLA-A2 cells plus a tenfold excess of unlabelled Jurkat cells pulsed with pr75-84 (#) and of Jurkat-HLA-A2 cells ($). HLA-A2 cells was maintained even in the presence of a tenfold excess of similarly peptide-pulsed, unlabelled Jurkat cells (Fig.  1) .
Besides the protease-derived peptides, we obtained peptide-specific CTLs against Pol 476-484 in one of three experiments, against influenza virus matrix (58-66, K62) in two experiments and against HPV-16 E7 (12-20) in two of three experiments. Regarding the six donors listed in Table 2 , peptide-specific CTLs were elicited in a total of 11 of the 30 different cultures started for peptide stimulation. The tested peptide-specific CTL cultures were CD8 + as determined by flow cytometry. The rest of the lymphocyte cultures revealed a non-peptide-specific killing pattern against a set of both HLA-matched and -unmatched EBV-transformed lymphoblastoid and Burkitt's lymphoma-derived cell lines (data not shown), suggesting a lymphokine-activated killer (LAK) phenotype. However, the specificity of these cultures was not further investigated.
In the initial experiments, we also determined the timecourse of the CTL stimulation ; cultures were assayed for cytolytic activity after 2, 3 or 4 weeks cultivation. In our experience, the break-point to get peptide-specific cytolysis was 4 weeks after set-up. If the cultures were sampled for &"Crrelease assay after 2 or 3 weeks, the viabilities of the remaining cultures were severely affected. Thus, the peptide-specific cytolysis assays were done with cultures of 4 weeks or older. For the 4th and subsequent restimulations of the peptidespecific CTLs, a mixture of peptide-pulsed PBMCs from two or three donors was used as feeder-stimulator cells. By this time the lymphocyte cultures were highly specific as assessed by the high cytolytic activity even at low effector : target ratios. The allogeneic feeder-stimulator cells did not affect CTL specificity for the rest of the cultivation period (Fig. 3 b) . These further cytotoxicity tests were done 7-9 days after the last restimulation step and consumed one-third to one-half of the cultures. Under these conditions, CTLs could be maintained for HIV-1 protease-peptide-specific CTLs HIV-1 protease-peptide-specific CTLs Table 3 . Peptide-specific lysis (%) of HLA-A2-matched target cells sensitized at different pr75-84 peptide concentrations Specific lysis (%) at an E : T ratio of : pr75-84 (nM) 10 : 1 5 : 1 2n5:1 1000 37n1 3 4 n 1 2 8 n 2 300 38n0 3 1 n 4 2 3 n 0 100 43n0 2 9 n 9 2 2 n 3 30 39n4 3 2 n 3 2 2 n 7 10 44n8 2 6 n 1 2 1 n 5 3 3 8 n 2 2 8 n 9 2 3 n 7 1 4 4 n 3 2 4 n 8 2 0 n 7 0 n 3 3 2 n 8 2 8 n 9 1 5 n 9 No peptide 11n1 9 n 3 1 0 n 8 10-12 weeks. In one case, a sample of a 6-week-old culture specific to pr75-84 could be recovered after 2 months storage in liquid nitrogen. The cumulative lifespan of this culture was the same (12 weeks) as that of the unfrozen part of the original culture. To further define the epitope, we synthesized a set of alanine replacement analogues. The binding affinity of these peptides is shown as the reciprocal value of C "/#max (Fig. 2) . One naturally occurring variant of the 10-mer peptide is known for the HIV-1 MAL strain, where V75 is changed to I. For this variant, both HLA-A*0201 binding and T-cell recognition were reduced but not abolished. The minimal length of the epitope was nine amino acids, since further truncations from either the C-or the N-terminal end resulted in markedly reduced HLA-A*0201 binding and loss of antigenicity (Fig. 2) .
Residues T80 or P81 seemed essential for both high affinity-binding and the ability to sensitize cells to CTL killing. The decrease in CTL recognition of peptides altered at the 77th, 78th or 79th residue can be explained by their reduced binding capacity. In contrast, the L76 and N83 side-chains were found to be crucial for CTL recognition but not for binding to HLA-A*0201.
For the pr75-84 peptide, we titrated the peptide concentration down to 300 pM without significant loss of target cell sensitization to CTL killing (Table 3) , indicating that the cultured CTLs had high avidity for the antigen.
The virus-suppressing effect of the peptide-stimulated lymphocyte cultures was tested on freshly separated or frozen CCCB stored, acutely infected PBMC samples (Fig. 3 a) . In the infection control wells, to which no cultured CTLs were added, p24 gag production was taken to be 100 %, which corresponded to 2n7-5n0 ng p24 gag in 1 ml supernatant by 10 days postinfection in different experiments. The CTL cultures added to the test wells at different effector : target ratios were specific to pr76-84, pr75-84 and the unrelated HPV-16 E7 derived peptide, respectively (Fig. 3 b) . The inhibition of virus replication was mediated by the protease-specific CTLs, whereas the unrelated, HPV-specific ones exerted little inhibitory effect. The inhibition pattern on HLA-A2-matched, but otherwise allogeneic, PBMC samples was very similar to that observed on autologous PBMCs, whereas in HLA-A2-mismatched, acutely infected PBMCs only low inhibition was found. Virus suppression by the cultured T-cells seemed dose dependent, i.e. it was stronger at the higher (1 : 1) effector : target ratio. To exclude the possibility that allogeneic killing was responsible for the virus-suppressing effect in the acutely infected, HLA-A2-matched PBMCs, effector lymphocyte cultures were collected from the inhibition wells after stopping the assay at day 10 and were tested in a standard cytotoxicity assay against PHA-stimulated aliquots of the same PBMC samples. Though the end-point results of the inhibition assays are shown (Fig.  3 a) , we were able to detect a similar effect at day 7 postinfection. The test performed on acutely infected CD4 + cells purified from freshly separated PBMCs also yielded similar results. The lymphocyte cultures with non-peptide-specific killing activity were also tested. These cultures also significantly inhibited virus replication.
Discussion
In HIV-infected hosts, much of the virus burden is intracellular and therefore therapeutic approaches should consider the infected cells as targets (Levy, 1995) . In general, cellular immune responses have an essential role in eliminating the infected cells. However, a high degree of variability is characteristic of most immunodominant T-cell epitopes of HIV. One possible solution is to identify the invariant, presumably subdominant, epitopes that might be used to elicit anti-HIV immunity (Nowak et al., 1995 ; Vanderburg et al., 1995) . The Pol region is more conserved, possibly because some mutations may also affect the functions of the essential enzymes encoded by this region. If such functionally conserved sequences are presented by the MHC and recognized by CTLs, the likelihood that escape mutants will emerge would be reduced. Indeed, CTL responses against RT Walker et al., 1988) , integrase and viral protease (Lamhamedicherradi et al., 1995) have been found in HIVinfected persons. For RT, an invariant cryptic epitope has also been identified (Vanderburg et al., 1995) .
Since our peptide set contained the peptides with preferred or tolerated amino acids at the anchor positions (Kast et al., 1994) , we have probably tested all possible HLA-A*0201-binding peptides from the protease of the HIV-1 strain MN. Our screening was also efficient, since 6 of the 26 peptides selected for synthesis bound to HLA-A*0201 with high affinities, which is comparable with those of known CTL epitopes.
All six strongly binding peptides were well-conserved among different variants. Even in the peptides subjected to mutations, only single, conservative amino acid changes occurred. Two of the six peptides were immunogenic with regard to CTL stimulation in vitro. These two peptides containing the same epitope, with a minimal length of nine amino acids, stimulated CTLs from all but one of the tested donors, who were selected for HLA-A2 by immunostaining. On the other hand, peptide binding was tested on the T2 cell line with subtype HLA-A2.1 (A*0201). Though several HLA-A2 subtypes, e.g. the ones encoded by A*0201, A*0202 or A*0205 alleles, share common antigen-presenting properties (del Guercio et al., 1995) , the unresponsive donor might have had a different HLA-A2 subtype. Based on the Los Alamos HIV sequence database (Myers et al., 1996) , this nine residue stretch of the protease is conserved among the virus strains originating from human infections. The natural virus strains with changes in this sequence belong to the HIV-1 CPZ group. The totally conserved binding peptide (pr23-32) covers the active site of the protease. Of the six binding peptides, however, this one had the lowest affinity to HLA-A*0201. The binding data of this peptide have been reported previously (Vanderburg et al., 1995) , but CTLs were not raised against it.
Fine mapping of our in vitro immunogenic epitope revealed that the HIV-1 MAL variant of pr75-84 slightly decreased both binding and CTL recognition. Several additional residues (V77, G78 and P79) were found to partially reduce MHC binding and the antigenicity of the epitope. However, only two internal residues (T80 and P81) were found to be essential for MHC binding. They may serve as secondary anchor residues. The epitope might have a rigid conformation as it contains two prolines (P79 and P81), known to form rigid amide bonds. Indeed, the greatest reduction in binding ability was caused by altering either of the two prolines or the residue (T80) between them. The side-chains of L76 and N83 seemed to interact with the T-cell receptor, since changing these residues to A abolished T-cell recognition but did not affect binding significantly. V82 is conserved among the established virus strains, but it can change in some in vitro-generated HIV variants that are protease-inhibitor-resistant (Myers et al., 1996) . However, the side-chain of V82 was not necessary for HLA-A*0201 binding or for T-cell recognition. Changing the anchor I84 to V also confers resistance to some protease inhibitors. However, V is also a preferred anchor amino acid, i.e. this mutation is not expected to reduce binding of the mutant peptide or to influence antigenicity.
In the virus inhibition experiments, the highly peptidespecific CTLs against the protease epitope efficiently suppressed virus replication as measured by p24 gag production, CCCC HIV-1 protease-peptide-specific CTLs HIV-1 protease-peptide-specific CTLs though inhibition, albeit to a lesser extent, was found also in the MHC-or epitope-mismatched controls. According to extensive investigations on in vitro virus suppression (reviewed by Levy et al., 1996) , CD8 + cells may inhibit virus replication by at least two different mechanisms : an MHC-restricted specific killing of virus-infected cells (Tsubota et al., 1989) and\or a non-MHC restricted non-cytolytic inhibition of HIV replication. The in vivo relevance of the former mechanism is supported by the fact that effector CTL activity correlates well with the clinical outcome, after taking the T-cell epitope complexity of the infecting virus variants into consideration (Nowak et al., 1995 ; . The non-cytolytic control mechanism involves down-regulation of transcription of the provirus in infected cells (Mackewicz et al., 1995) and is primarily mediated by a soluble, CD8 + T-cell antiviral factor (CAF), although other T-cell products such as IL-16 (Baier et al., 1995) and chemokines (Cocchi et al., 1995) can also contribute to the antiviral effect. This CTL effector function also requires prior activation of the CD8 + T-lymphocytes, which occurs in vivo in HIV-infected individuals, implying that the stimulation of the antiviral CD8 + T-cells is virus-specific, plausibly through MHC and T-cell receptor interaction, in contrast to the noncytolytic effector functions.
HIV-suppressive T-cell clones could be generated in vitro from uninfected, healthy blood donors by long-term nonspecific stimulation (Hsueh et al., 1994) . Here, we showed that CTL cultures with similar antiviral activity were raised in an epitope-specific way. In addition, CTLs specific to the protease peptides maintained peptide recognition and cytolysis after a 10 day co-cultivation with acutely infected cells, suggesting an MHC-and epitope-restricted stimulation by the virus-infected cells.
This study focused on MHC class I-restricted CTL epitopes recognized by CD8 + T-cells. Peptide-specific CTLs were raised from donor 2 in the absence of CD4 + helper cells indicating that induction of these CTLs did not require an intact CD4 + cell function. Knowledge of immunogenic peptide sequences opens the way to several immunotherapeutic approaches. For instance, a CTL epitope-containing vaccine against hepatitis B virus evoked CTLs in a phase I clinical trial (Vitiello et al., 1995) . Promising results have been obtained in adoptive transfer of in vitro-propagated CTLs to HIV-infected subjects (Ho et al., 1993) .
